Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

vatreptacog alfa

- PMLiVE

Sobi shows strong growth despite haemophilia competition

Looking to M&A for continued growth

- PMLiVE

Q&A: Niels Lund

PME interviews Novo Nordisk's Vice President, Health Advocacy

- PMLiVE

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin price nearly tripled between 2002 and 2013

- PMLiVE

Sanofi exits R&D pact with Alnylam on rare disease

Exit also frees up $700m equity investment

- PMLiVE

Novo uses voucher for speedy answer on oral semaglutide

Oral version of Ozempic could be diabetes market leader

- PMLiVE

BioMarin prepares for haemophilia A gene therapy data readout, filing

Key long-term data expected in July

- PMLiVE

Roche gets wider approval for haemophilia drug Hemlibra

Approved to treat bleeding episodes in patients without inhibitors

- PMLiVE

Novo Nordisk to launch connected insulin pens

Also partners with Dexcom, Glooko and Roche on digital platforms

- PMLiVE

Daily Brief: Another next-gen diabetes research deal for Novo, Vertex and Australia break deadlock

News from pharma, biotech and healthcare

- PMLiVE

Roche highlights Hemlibra data as key FDA date approaches

Expanded use would see revenues take off

- PMLiVE

Novo Nordisk and Evotec inks drug development deal

Will develop drugs for obesity and diabetes

- PMLiVE

Novo’s oral diabetes drug hits the mark again

The drug proves effective in reducing blood sugar in diabetes patients with renal impairment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links